| Periodo | Cap. mercato | Var. |
| 2026-06 | 911.55 M USD | +0.41% |
| 2026-06 | 907.84 M USD | -3.06% |
| 2026-06 | 936.47 M USD | +9.01% |
| 2026-06 | 859.05 M USD | -1.46% |
| 2026-06 | 871.78 M USD | -8.05% |
| 2026-06 | 948.14 M USD | +3.77% |
| 2026-06 | 913.67 M USD | +0.12% |
| 2026-06 | 912.61 M USD | +0.47% |
| 2026-06 | 908.37 M USD | -5.83% |
| 2026-05 | 964.58 M USD | -3.24% |
| 2026-05 | 996.92 M USD | +4.16% |
| 2026-05 | 957.15 M USD | +0.22% |
| 2026-05 | 955.03 M USD | +2.91% |
| 2026-05 | 927.99 M USD | — |
Seaport Therapeutics, Inc. is a clinical-stage biotechnology company focused on inventing and developing novel oral medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company employs its proprietary Glyph platform to address limitations of clinically validated mechanisms, such as high first-pass metabolism, low bioavailability, and side effects, enabling innovative therapies with established efficacy and safety profiles. Seaport Therapeutics targets the neuropsychiatry sector within pharmaceuticals and biotech, aiming to deliver leading treatment options that improve patient outcomes. Its pipeline advances antidepressants and anxiolytics derived from these optimized mechanisms. With a team experienced in neuropsychiatry drug discovery and development, Seaport Therapeutics operates at the intersection of cutting-edge platform technology and targeted therapeutic innovation. Founded in 2024 and headquartered in Boston, Massachusetts, the company plays a role in advancing accessible oral treatments for serious mental health conditions in the competitive biopharmaceutical market.